Malignant Hyperthermia (MH) is a rare pharmacogenetic disorder. MH reactions are potentially fatal if prompt appropriate treatment is not instituted. An MH crisis is increasingly rare and many anaesthetists will not experience one in their practising career. There are many high priority tasks that must be attended to simultaneously. For these reasons, the group of anaesthetists responsible for MH investigation in Australia and New Zealand (mhanz) have completed the attached MH Resource Kit. In some cases the recommendations represent re-worked or refined versions of pre-existing documents. The mhanz group acknowledges the staff of Palmerston North Hospital (New Zealand) and the Southern Health Simulation Centre (Victoria) for their contribution to our final package.